Submit a late-breaking abstract through March 14! Send us your research that is high impact, groundbreaking, innovative, and newsworthy!
In Q4, FDA approved U.S.-first gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease.
The fourth quarterly report of 2023 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
Highlights from this issue include:
FDA approved two cell-based gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease
Casgevy is the first approved therapy in the U.S. that uses CRISPR
Two RNA therapies were also approved in the U.S.
Download the full report
May 13-17, 2025 | New Orleans
© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico